




RealRate

PHARMACEUTICAL 2019

BioXcel Therapeutics Inc.
Rank 182 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2019

BioXcel Therapeutics Inc.
Rank 182 of 371



The relative strengths and weaknesses of BioXcel Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BioXcel Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 323% points. The greatest weakness of BioXcel Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is -147%, being 184% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	43,171
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,660
Liabilities, Non-Current	0
Other Assets	51
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	692
Property and Equipment	327
Research and Development	14,558
Revenues	0
Selling, General and Administrative Expense	5,404

Output Variable	Value in 1000 USD
Assets	43,549
Liabilities	4,660
Expenses	19,962
Stockholders Equity	38,889
Net Income	-19,270
Comprehensive Net Income	-19,270
Economic Capital Ratio	-147%

